New CTIP2-associated complexes; Validate newly identified proteins/ncRNA ; The association of CTIP2 expression and chronic inflammation of HIV-1 treated patients; Test and select drugs to be validated in WP5

Characterise CTIP2-associated complexes by gel filtration/immunoprecipitations combined with mass spectrometry (protein content) and high throughput sequencing (non coding RNA). Validate newly identified proteins/ncRNA by lost-/gain-of-function studies using in vitro HIV-1 latency cellular models. Define the impact of the HIV-1 cART on the presence of CTIP2 (and its associated complexes), in CD4+ T cells and monocytes from HIV-1 patients (MMUH cohorts) Study of the correlation between CTIP2-level and CTIP2-associated complexes with the inflammatory status of HIV-1 patients (MMUH cohorts). Test and select new latency-reversible compounds targeting functionally validated CTIP2-associated proteins using in vitro latency models.